A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
- PDF / 254,265 Bytes
- 10 Pages / 610 x 792 pts Page_size
- 45 Downloads / 192 Views
BioMed Central
Open Access
A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" Lisa H Butterfield*1, Mary L Disis2, Bernard A Fox3,4, Peter P Lee5, Samir N Khleif6, Magdalena Thurin7, Giorgio Trinchieri8, Ena Wang9, Jon Wigginton10, Damien Chaussabel11, George Coukos12, Madhav Dhodapkar13, Leif Håkansson14, Sylvia Janetzki15, Thomas O Kleen16, John M Kirkwood1, Cristina Maccalli17, Holden Maecker18, Michele Maio19,20, Anatoli Malyguine21, Giuseppe Masucci22, A Karolina Palucka11, Douglas M Potter23, Antoni Ribas24, Licia Rivoltini25, Dolores Schendel26, Barbara Seliger27, Senthamil Selvan28, Craig L Slingluff Jr29, David F Stroncek30, Howard Streicher31, Xifeng Wu32, Benjamin Zeskind33, Yingdong Zhao34, Mai-Britt Zocca35, Heinz Zwierzina36 and Francesco M Marincola*9 Address: 1Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA, 2Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle, Washington, 98195, USA, 3Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, 97213, USA, 4Department of Molecular Biology, OHSU Cancer Institute, Oregon Health and Science University, Portland, Oregon, 97213, USA, 5Department of Medicine, Division of Hematology, Stanford University, Stanford, California, 94305, USA, 6Cancer Vaccine Section, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, 20892, USA, 7Cancer Diagnosis Program, NCI, NIH, Rockville, Maryland, 20852, USA, 8Cancer and Inflammation Program, NCI, NIH, Frederick, Maryland, 21702, USA, 9Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Center for Human Immunology, National Institutes of Health, Bethesda, MD, USA, 10Bristol Myers-Squibb, Princeton, New Jersey, 08540, USA, 11Baylor Institute for Immunology Research and Baylor Research Institute, Dallas, Texas, 75204, USA, 12Center for Research on the Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia 19104, USA, 13Department of Hematology, Yale University, New Haven, Connecticut 06510, USA, 14Division of Clinical Tumor Immunology, University of Lund, 581 85, Sweden, 15ZellNet Consulting Inc. Fort Lee, New Jersey, 07024, USA, 16Cellular Technology Limited, Shaker Heights, Ohio, 44122, USA, 17Unit of Immuno-Biotherapy of Solid Tumors, Department of Molecular Oncology, San Raffaele Scientific Institute DIBIT, Milan, 20132, Italy, 18Baylor Institute for Immunology Research, Dallas, 75204, Texas, USA, 19Medical Oncology and Immunotherapy, Department. of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy, 20Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, IRCCS, Aviano, 53100, Italy, 21Laboratory of Cell Mediated Immunity, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD, 21702, USA, 22Departme
Data Loading...
